FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2505-2509 June 5, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kishimoto, T. K. PubMed Citation

Hypotensive episodes in patients receiving heparin by means of injection, some of which cause death, are voluntarily reported to the Food and Drug Administration (FDA). Many cases occur in medical situations associated with hypotension, such as hemodialysis or pulmonary embolus. Such reports of hypotensive episodes and, unfortunately, of associated deaths increased dramatically from November 2007 through February 2008.¹ Close cooperation among the FDA, the Centers for Disease Control and Prevention, pharmaceutical companies, and physicians led to the tracing of the problematic preparations of heparin to the Scientific Protein Laboratories' manufacturing operation in Changzhou, China. Consequently, by March 2008, exposures of . . . [Full Text of this Article]

Source Information

From the Department of Internal Medicine, Virginia Commonwealth University, Richmond.

This article has been cited by other articles:

• Blossom, D. B., Kallen, A. J., Patel, P. R., Elward, A., Robinson, L., Gao, G., Langer, R., Perkins, K. M., Jaeger, J. L., Kurkjian, K. M., Jones, M., Schillie, S. F., Shehab, N., Ketterer, D., Venkataraman, G., Kishimoto, T. K., Shriver, Z., McMahon, A. W., Austen, K. F., Kozlowski, S., Srinivasan, A., Turabelidze, G., Gould, C. V., Arduino, M. J., Sasisekharan, R. (2008). Outbreak of Adverse Reactions Associated with Contaminated Heparin. NEJM 359: 2674-2684 [Abstract] [Full Text]